Performing + structured credit fund research profile
Piramal Alternatives is an institutional-capital platform spanning performing credit, structured credit, growth capital and IndiaRF special situations. Its credit franchise lends to mid-sized and larger Indian corporates, with public evidence of CDPQ-backed capital, sector-agnostic underwriting and multiple realizations across the broader platform.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Piramal Alternatives (credit) uses a performing + structured credit approach across Performing credit, structured credit, healthcare.
Current evidence
Piramal Alternatives’ 2024 Performing Credit Fund investment in Biodeal Pharmaceuticals was publicly announced at ₹110 crore, and its 2025 India Credit Opportunities Fund II investment in SaiMirra Innopharm was announced at ₹160 crore. Biodeal later reported a full redemption in 2026 at over 20% IRR. Piramal’s current fund page identifies the relevant Category II credit vehicles; broader platform AUM is not a credit-only return measure.
Strategy
Performing + structured credit
Sector focus
Performing credit, structured credit, healthcare
AIF structure context
Indian private credit, venture-debt and special-situations funds are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Piramal Alternatives’ 2024 Performing Credit Fund investment in Biodeal Pharmaceuticals was publicly announced at ₹110 crore, and its 2025 India Credit Opportunities Fund II investment in SaiMirra Innopharm was announced at ₹160 crore. Biodeal later reported a full redemption in 2026 at over 20% IRR. Piramal’s current fund page identifies the relevant Category II credit vehicles; broader platform AUM is not a credit-only return measure.
Investor questions
Piramal Alternatives private credit is covered in Rupeia's private credit research universe. The current public record describes the strategy as Performing + structured credit, with a sector focus of Performing credit, structured credit, healthcare. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Piramal Alternatives private credit in the reviewed public sources: Biodeal Pharmaceuticals; SaiMirra Innopharm. It does not represent a complete current portfolio unless the manager has published one.
Piramal reports $1.5 billion life-to-date AUM and 19 active portfolio companies on its current alternatives page; its annual report describes roughly $1 billion of committed capital and more than 70% deployment for the performing-credit fund. These are platform and vehicle disclosures, not a single consolidated IRR. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: Public disclosures cite approximately $1 billion committed/deployed for the performing-credit platform and $1.5 billion life-to-date alternatives AUM.. Public terms or access information: Performing, structured and growth credit for mid-to-large corporates; vehicle fees, carry, tenor and target return are not fully public.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Kalpesh Kikani (CEO, Piramal Alternatives). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review borrower concentration, security and seniority, cash versus accrued income, defaults, recoveries, fund leverage and liquidity. The current open diligence point is: Fund-wise AUM, fees/carry, tenor and a complete credit-only portfolio remain not publicly disclosed; broader alternatives-platform statistics are not treated as credit-fund performance..
2026-07-29: Piramal Alternatives’ 2024 Performing Credit Fund investment in Biodeal Pharmaceuticals was publicly announced at ₹110 crore, and its 2025 India Credit Opportunities Fund II investment in SaiMirra Innopharm was announced at ₹160 crore. Biodeal later reported a full redemption in 2026 at over 20% IRR. Piramal’s current fund page identifies the relevant Category II credit vehicles; broader platform AUM is not a credit-only return measure.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.